NL139166B - Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking. - Google Patents
Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking.Info
- Publication number
- NL139166B NL139166B NL696914077A NL6914077A NL139166B NL 139166 B NL139166 B NL 139166B NL 696914077 A NL696914077 A NL 696914077A NL 6914077 A NL6914077 A NL 6914077A NL 139166 B NL139166 B NL 139166B
- Authority
- NL
- Netherlands
- Prior art keywords
- preparing
- medicinal product
- blocking action
- beta adrenergic
- adrenergic blocking
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/38—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
- C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76185768A | 1968-09-23 | 1968-09-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL6914077A NL6914077A (es) | 1970-03-25 |
| NL139166B true NL139166B (nl) | 1973-06-15 |
Family
ID=25063434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL696914077A NL139166B (nl) | 1968-09-23 | 1969-09-17 | Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3641152A (es) |
| JP (1) | JPS4843734B1 (es) |
| BE (1) | BE739195A (es) |
| CH (1) | CH525183A (es) |
| DE (2) | DE1967162C3 (es) |
| DK (2) | DK125588B (es) |
| ES (1) | ES371737A1 (es) |
| FI (1) | FI51936C (es) |
| FR (1) | FR2018626B1 (es) |
| GB (1) | GB1223527A (es) |
| IT (1) | IT1033032B (es) |
| NL (1) | NL139166B (es) |
| NO (1) | NO128869B (es) |
| SE (1) | SE362414B (es) |
| ZA (1) | ZA695648B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE755071A (fr) * | 1969-09-17 | 1971-02-22 | Warner Lambert Pharmaceutical | Procede de resolution de la dl-5-/3-(terbutylamino)-2- hydroxy-propoxy/-3,4-dihydro-1(2h) naphtalenone |
| US3959486A (en) * | 1970-05-27 | 1976-05-25 | Imperial Chemical Industries Limited | Method for producing β-adrenergic blockage with alkanolamine derivatives |
| DE2130393C3 (de) * | 1970-06-22 | 1981-02-26 | E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) | 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen |
| FR2119843B1 (es) * | 1970-12-28 | 1974-03-22 | Laroche Navarro Labo | |
| JPS5122737Y2 (es) * | 1972-12-30 | 1976-06-11 | ||
| US3966749A (en) * | 1975-02-10 | 1976-06-29 | Interx Research Corporation | Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof |
| GB1493848A (en) * | 1975-07-24 | 1977-11-30 | Beecham Group Ltd | Aryltetralins |
| CH621330A5 (es) * | 1976-05-14 | 1981-01-30 | Sandoz Ag | |
| DE2810869A1 (de) * | 1977-03-24 | 1978-09-28 | Sandoz Ag | 3-amino-2-hydroxypropoxy-derivate, ihre herstellung und verwendung |
| US4176183A (en) * | 1977-05-02 | 1979-11-27 | Merck & Co., Inc. | Novel naphthyridines |
| US4270005A (en) * | 1977-11-14 | 1981-05-26 | Pfizer Inc. | 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor |
| CH641147A5 (de) * | 1979-01-17 | 1984-02-15 | Sandoz Ag | 3-amino-2-hydroxypropoxyaryl-derivat, seine herstellung und dieses enthaltende heilmittel. |
| DE2943406A1 (de) * | 1979-10-26 | 1981-05-07 | Basf Ag, 6700 Ludwigshafen | Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols |
| FR2507181A1 (fr) | 1981-06-05 | 1982-12-10 | Sanofi Sa | Nouveaux ethers de phenol actifs sur le systeme cardiovasculaire, leur procede de preparation et leur utilisation dans des medicaments |
| SE8801518D0 (sv) * | 1988-04-22 | 1988-04-22 | Astra Pharma Prod | A novel process |
| US5225565A (en) * | 1988-09-15 | 1993-07-06 | The Upjohn Company | Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones |
| ES2065278B1 (es) * | 1993-06-24 | 1995-09-01 | Medichem Sa | Procedimiento de obtencion enantioselectivo del levobunolol. |
| CA2415789A1 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1023214A (en) | 1962-12-17 | 1966-03-23 | Ici Ltd | Carbocyclic hydroxyamines |
-
1968
- 1968-09-23 US US761857A patent/US3641152A/en not_active Expired - Lifetime
-
1969
- 1969-08-06 ZA ZA695648A patent/ZA695648B/xx unknown
- 1969-08-22 GB GB41987/69A patent/GB1223527A/en not_active Expired
- 1969-09-11 FR FR696930899A patent/FR2018626B1/fr not_active Expired
- 1969-09-17 NL NL696914077A patent/NL139166B/xx not_active IP Right Cessation
- 1969-09-18 JP JP44073683A patent/JPS4843734B1/ja active Pending
- 1969-09-22 NO NO693770A patent/NO128869B/no unknown
- 1969-09-22 DK DK503669AA patent/DK125588B/da unknown
- 1969-09-22 BE BE739195D patent/BE739195A/xx not_active IP Right Cessation
- 1969-09-22 ES ES371737A patent/ES371737A1/es not_active Expired
- 1969-09-22 CH CH1430069A patent/CH525183A/de not_active IP Right Cessation
- 1969-09-22 SE SE13017/69A patent/SE362414B/xx unknown
- 1969-09-22 IT IT22348/69A patent/IT1033032B/it active
- 1969-09-23 DE DE1967162A patent/DE1967162C3/de not_active Expired
- 1969-09-23 DE DE1948144A patent/DE1948144C3/de not_active Expired
- 1969-09-23 FI FI692717A patent/FI51936C/fi active
-
1971
- 1971-11-12 DK DK556771AA patent/DK128536B/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4843734B1 (es) | 1973-12-20 |
| NO128869B (es) | 1974-01-21 |
| SE362414B (es) | 1973-12-10 |
| NL6914077A (es) | 1970-03-25 |
| US3641152A (en) | 1972-02-08 |
| FR2018626A1 (es) | 1970-06-26 |
| DE1967162C3 (de) | 1981-03-19 |
| GB1223527A (en) | 1971-02-24 |
| FI51936B (es) | 1977-01-31 |
| CH525183A (de) | 1972-07-15 |
| IT1033032B (it) | 1979-07-10 |
| DE1948144B2 (de) | 1979-05-03 |
| BE739195A (es) | 1970-03-23 |
| ES371737A1 (es) | 1972-03-16 |
| DE1967162B1 (de) | 1980-07-31 |
| DK128536B (da) | 1974-05-20 |
| DK125588B (da) | 1973-03-12 |
| FR2018626B1 (es) | 1973-06-08 |
| DE1948144C3 (de) | 1980-01-17 |
| ZA695648B (en) | 1971-03-31 |
| FI51936C (fi) | 1977-05-10 |
| DE1948144A1 (de) | 1970-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL151374B (nl) | Werkwijze voor het bereiden van een geneesmiddel met een prolactineremmende werking alsmede van een hierbij bruikbaar alfa-ergokryptinederivaat. | |
| NL146378B (nl) | Werkwijze voor het bereiden van een geneesmiddel met diuretische werking. | |
| NL7809942A (nl) | Werkwijze voor het bereiden van een geneesmiddel met blokkerende werking op beta-adrenergische receptoren onder toepassing van een fenylaminoethanolderivaat. | |
| NL158176B (nl) | Werkwijze voor het bereiden van een geneesmiddel met (beta)-adrenenergisch blokkerende werking, gevormd geneesmiddel verkregen onder toepassing daarvan, alsmede werkwijze voor het bereiden van een verbinding geschikt voor toepassing bij voornoemde werkwijze. | |
| NL139166B (nl) | Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking. | |
| NL142590B (nl) | Werkwijze voor het bereiden van een geneesmiddel met anti-bacteriele werking. | |
| NL140237B (nl) | Werkwijze voor het bereiden van een geneesmiddel met kalmerende werking. | |
| NL174550C (nl) | Werkwijze ter bereiding van een lactatieremmende verbinding, werkwijze voor het bereiden van een geneesmiddel met lactatieremmende werking en gevormd geneesmiddel. | |
| NL170734C (nl) | Werkwijze voor het bereiden van een geneesmiddel met antibacteriele werking en werkwijze voor het bereiden van daarbij te gebruiken geneeskrachtige verbindingen. | |
| NL163788C (nl) | Werkwijze ter bereiding van een geneesmiddel met neuro- trope en psychotrope werking, alsmede werkwijze voor het bereiden van een geneeskrachtig dibenzothiepien of dibenzooxepienderivaat. | |
| NL142672B (nl) | Werkwijze voor het bereiden van een geneesmiddel met een cholesterolspiegelverlagende werking, en werkwijze voor het bereiden van geneeskrachtige verbindingen daarvoor. | |
| NL143924B (nl) | Werkwijze voor het bereiden van een geneesmiddel tegen hypertensie. | |
| NL172653C (nl) | Werkwijze voor het bereiden van een geneesmiddel met antimycotische werking en werkwijze voor het bereiden van geneeskrachtige joodpropargyloxyareenderivaten. | |
| NL154116B (nl) | Werkwijze voor het bereiden van een geneesmiddel met anti-bacteriele werking, alsmede het gevormde geneesmiddel. | |
| NL141188B (nl) | Werkwijze voor het bereiden van een geneesmiddel. | |
| NL138934B (nl) | Werkwijze voor het bereiden van een geneesmiddel met anti-inflammatoire werking. | |
| NL175721C (nl) | Werkwijze voor het bereiden of vervaardigen van een geneesmiddel met anticholinergische werking. | |
| NL142687B (nl) | Werkwijze ter bereiding van een farmaceutisch of veterinair geneesmiddel met anthelmintische werking. | |
| NL144613B (nl) | Werkwijze voor het bereiden van een derivaat van d-6-methylergoleen met bloeddrukverlagende werking. | |
| NL175254C (nl) | Werkwijze voor het bereiden van een preparaat met fungicide werking. | |
| NL175825C (nl) | Werkwijze voor het bereiden of vervaardigen van een geneesmiddel met antilipidemische werking. | |
| NL160255C (nl) | Werkwijze voor het bereiden van een geneesmiddel met anti-depressieve werking. | |
| NL144608B (nl) | Werkwijze voor het bereiden van een geneesmiddel met anti-inflammatoire werking. | |
| NL160331C (nl) | Werkwijze voor het bereiden van een preparaat met reini- gende werking. | |
| NL142401B (nl) | Werkwijze voor het bereiden van een geneesmiddel met bloedlipidenspiegel-verlagende werking. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NL80 | Abbreviated name of patent owner mentioned of already nullified patent |
Owner name: WARNER LAMBERT |
|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |